ATXI:NSD-Avenue Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.89

Change

+0.04 (+2.16)%

Market Cap

USD 0.03B

Volume

0.07M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

Company Website : http://www.avenuetx.com

Address : 1140 Avenue of the America, New York, NY, United States, 10036

Employees : 4

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.63

52 Week High : 12.34

Short Ratio : 1.08

52 Week Low : 1.75

Shorted Shares : 421,810

200 Day Moving Average : 4.82

Shorted Shares Previous Month : 358,136

50 Day Moving Average : 2.62

Shares Held By Insiders : 60.31%

Short Percentage : 3.00%

Shares Held by Institutions : 11.25%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+20.82 (+6.34%)

 USD131.90B 220.17 184.41
BNTX BioNTech SE

+29.45 (+10.37%)

 USD68.59B 51.85 43.53
REGN Regeneron Pharmaceuticals, Inc

+5.40 (+0.93%)

 USD61.90B 16.54 12.91
VRTX Vertex Pharmaceuticals Incorpo..

-0.61 (-0.30%)

 USD52.51B 19.34 13.17
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.69 (+1.57%)

 USD28.97B 32.86 3.81
BGNE BeiGene, Ltd

+43.46 (+16.14%)

 USD27.52B N/A N/A
SGEN Seagen Inc

+1.68 (+1.16%)

 USD26.21B 40.30 35.56
RPRX Royalty Pharma plc

-0.67 (-1.71%)

 USD23.80B 32.32 14.58
ALNY Alnylam Pharmaceuticals, Inc

+5.51 (+3.12%)

 USD20.76B N/A N/A

ETFs Containing ATXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -68.24% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.24% 3% F 2% F
Trailing 12 Months  
Capital Gain -82.25% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.25% 1% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.81% 51% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.81% 51% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 49.38% 64% D 36% F
Risk Adjusted Return 30.00% 55% F 47% F
Market Capitalization 0.03B 3% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 21.12 7% F 6% F
Price / Cash Flow Ratio -6,716.67 100% A+ 98% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -135.40% 16% F 16% F
Return on Invested Capital -0.11% 83% B 51% F
Return on Assets -71.47% 5% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.08 79% C+ 72% C-
Short Percent 6.36% 51% F 31% F
Beta 0.63 82% B- 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.